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Nutritional enhancement in plants – green and greener
Johnathan A Napier1 and Olga Sayanova1
The global challenges of ensuring sufficient safe and nutritious
food for all are enshrined within the Sustainable Development
Goals. As our planet’s population continues to grow, and as the
impacts of climate change and environmental pollution
become more visible to all, new solutions continue to be sought
as to how best address these. Transgenic crops specifically
focussed on delivering health-beneficial compounds will likely
play a role in this, and this review will consider several areas
where good progress has been made. In particular, the
transition from basic research to commercial product is a
journey that more and more projects are embarking on,
hopefully leading to the fulfilment of earlier promises as to the
potential of genetically modified (GM) plants to deliver
improved human nutrition.
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Introduction
The potential of plant genetic engineering to enhance the
nutritional composition of plants has been appreciated
since the dawn of the era of transgenesis in the early
1980s, but very limited progress has been made in bring-
ing such traits to the market. This is in stark contrast with
the so-called input traits (such as herbicide tolerance and
insect) which comprise the vast majority (99.9%) of all
GM crops grown on the planet today [1]. The reasons for
this disparity are many and varied, including the cost of
regulatory approval, concerns over consumer acceptance
and the more complex nature of the nutritional enhance-
ment traits, but recently progress has been made [1].
Moreover, the increased focus on the bioeconomy and the
wider ‘greening’ of society (meaning a more sustainable,
less environmentally intrusive approach) has resulted in
some philosophical shifts when it comes to using new
technologies to provide alternative sources of important
nutrients we take for granted [2]. This short review
article will consider some exemplars for how plant bio-
technology can contribute to improved human health and
reduced environmental impact.
Omega-3 fish oils
The health benefits associated with a diet containing
omega-3 fish oils (or specifically omega-3 long chain
polyunsaturated fatty acids) are well-established and
are exemplified as nutrients we should consume more
over. This is because they contribute to reduced risk of
cardiovascular disease (CVD) as well as positive anti-
inflammatory lipid mediators and roles in brain and retinal
function. Current sources of these omega-3 LC-PUFAs
such as eicosapentaenoic acid (EPA) and docosahexae-
noic acid (DHA) are almost exclusively derived from our
oceans via wild capture of marine fish. This has an
obvious implication for the sustainability of such methods
as well as consequences for marine pollution and indus-
trial footprint. In addition, as a sad reflection on the state
of our oceans, fish accumulate the pollutants present in
the water, with the potential to introduce compounds
such heavy metals, into the human food chain. For these
reasons, considerable effort has been directed to making
non-marine sources of omega-3 LC-PUFAs [3], including
transgenic plants, predominately using the aerobic desa-
turase/elongase pathway present in marine microbes
(Fig. 1). The past decade has seen significant progress
in moving from ‘proof-of-concept’ studies showing the
moderate accumulation of EPA and DHA in model
systems [4,5] to the successful transfer of the technology
to bona fide crops such as canola and camelina [6–8].
Excitingly, in more recent years, studies have moved
beyond the laboratory (‘research’) phase and into a poten-
tially more impactful ‘development’ phase, meaning that
these projects are now poised to deliver tangible benefits
from the progress. These transitions include carrying out
GM field trials (i.e. environmental releases) to provide
data on the agronomic performance of the transgenic crop
under real-world conditions [9,10] and also feeding stud-
ies to confirm the equivalence and efficacy of plant-
derived ‘fish oils’ compared with bona fide marine oils.
Such studies include feeding trials with mice [11],
humans [12] and a number of fish species such as salmon
[13,14,15] and sea bream [16]. The reason for the strong
focus on fish-feeding studies is that the majority of
oceanically sourced fish oils are used in aquaculture, again
highlighting the sustainability aspect of these projects [3].
Without new de novo sources of omega-3 fish oils, the
growth of aquaculture industry is likely to be constrained,
which is problematic given the growth of the global
population and the demand for animal protein [3].
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Farmed fish represents the most efficient (in terms of
inputs versus edible outputs) production system by which
to generate animal protein for human consumption, but
the cultivation of marine fish species requires the pres-
ence of omega-3 fish oils in the diet, otherwise the
animals are unhealthy and lack the very nutrients which
make them attractive to the health-conscious consumer.
The last ten years has seen a worrying decline in the
levels of EPA and DHA in farmed fish [17], due to
pressures on availability of oceanic fish oils. Hence,
new sources of omega-3 fish oils are keenly sought.
In that respect, the further progress of GM canola lines
engineered to accumulate EPA and DHA is important. In
two independent efforts [reviewed in Ref. 18], trans-
genic canola plants making these omega-3 fish oils have
successfully been taken through the US regulatory
approval system, meaning that these plants can now be
grown commercially. This represents the first examples of
GM plants with nutritional enhancement traits progres-
sing from research concept to deregulated commercial
product, and hopefully marks the start of further exam-
ples in the future. Given the demand for new sustainable,
clean sources of omega-3 fish oils from the aquaculture
industry, it is likely that these plant oils are used pre-
dominantly in fish feed [3], but it is equally possible to
imagine them being used for direct human nutrition
[2,12].
Non-methylene-interrupted fatty acids and
cannabinoid mimetics
An emerging area of interest, closely related to the LC-
PUFAs described above, are non-methylene-interrupted
(NMI) fatty acids. These are polyunsaturated fatty acids
where their arrangement of double bonds does not follow
the usual pattern of occurring every third carbon, sepa-
rated by a methylene group. Examples of such NMI-
PUFAs include the C20 sciadonic acid (SCA;20:3D5,11,14)
and juniperonic acid (JPA;20:4D5,11,14,17) and C18 pino-
lenic acid (PNA; 18:3D5,9,11) [19]. In the case of SCA there
is evidence that this fatty acid can displace the omega-6
arachidonic acid (ARA;20:4D5,8,11,14) from pro-inflamma-
tory cascades and that 2-sciadonoylglycerol (i.e. a mono-
glyceride with SCA at the sn-2 position) is a ligand for the
human CB1 cannabinoid receptor. This has led to the
classification of such NMI-PUFA-containing lipids as
endocannabinoids [20] with cannabimimetic properties
[21]. Given the growing interest in non-psychotropic
cannabinoids for a range of human uses, new sources of
such lipids are sought (Figures 1 and 2). One of the
enzymatic activities involved in the biosynthesis of
SCA, NMI-PUFA D5-desaturase has been identified in
seeds of Anemone leveillei, a member of an angiosperm
family of Ranunculaceae and co-expression of this desatur-
ase and a D9-elongase in transgenic Arabidopsis resulted
in accumulation of SCA and JPA [19]. Very recently, de
novo transcriptome sequencing of seed RNA from the
gymnosperm Torreya grandis (Chinese yew tree) has iden-
tified a number of potential genes involved in the bio-
synthesis of SCA [22]. Further works remains to be done
to confirm the function of these T. grandis putative
desaturases and elongases and the configuration of the
PUFA-biosynthetic pathway they represent, but such
advances may provide a molecular toolkit for the trans-
genic synthesis of NMI-PUFAs, analogous to previously
demonstrated for the omega-3 fish oils [23].
Astaxanthin and related carotenoids
The ketocarotenoid astaxanthin is used in a number of
different feed and food applications, predominantly as a
colourant in aquafeed diets but also as an antioxidant and
nutraceutical with anti-inflammatory properties. Natural
sources of astaxanthin include a diverse range of bacteria
and marine microalgae, and its characteristic red-pink
colour is present throughout many aquatic foodwebs
(examples include the pigmentation present in salmonid
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Figure 1
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Schematic representation of the biosynthetic pathway for omega-3
LC-PUFAs in transgenic plants. Precursor fatty acids LA and ALA are
shown in green. A minimum of three to five enzymatic steps are
required to convert these C18 fatty acids to the desired C20 omega-3
EPA or C22 omega-3 DHA (red), Enzymes will recognise both omega-
6 and omega-3 substrates, hence the requirement for w3-desaturases
to convert omega-6 products to the omega-3 form (e.g. ARA to EPA).
This represents a ‘salvage’ pathway for further generation of desired
omega-3 LC-PUFAs.
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species and krill), indicating amenability to accumulation
via dietary intake [24]. Despite the presence of different
biological sources, the majority of commercial astaxanthin
is chemically synthesised – however, this usually gener-
ates a mixture of three different optical isomers, which
has reduced capacity as an antioxidant. Perhaps more
importantly, the isomerically homogenous natural astax-
anthin is considered more efficacious in nutraceutical
applications and human health [24]. Previous attempts
to engineer transgenic plants to synthesis astaxanthin
have met with some success, focussing on the expression
of heterologous enzymes to convert the endogenous
carotenoid b-carotene. This has predominantly (but not
exclusively) used bacterial activities such as b-carotene
hydroxylase (CrtZ) and oxyxgenase (CrtW), targeted to
the plastid [24]. Proof-of-concept accumulation of astax-
anthin and related ketocarotenoids has been demon-
strated in a number of different plant species, though
the overall yield is not currently sufficient to compete
with other sources [25]. Recent studies have indicated the
potential of GM plants to provide a ‘green’ source of this
pigment for use in aquaculture, with transgenic tomato
fruit engineered to accumulate astaxanthin which was
subsequently used to formulate diets for aquafeed studies
on trout [26]. Interestingly, much of the ketocarotenoid
generated in this study was not astaxanthin but instead
the structurally related phoenicoxanthin and canthaxan-
thin. Moreover, these ketocarotenoids were predomi-
nantly esterifed with fatty acids, as opposed to the free
form. Irrespective of that, when evaluated as an aquafeed
ingredient, these compounds performed equivalent to
astaxanthin in terms of the pigmentation of the flesh
[26], indicating that at least for some applications, the
purity and form of the ketocarotenoid is not critical.
Astaxanthin for use in aquaculture has also been made
in GM soybeans, stacked with an omega-3 trait [27]. Since
these two ingredients are the most expensive components
of aquafeed diets, the possibility to make them both in
one platform represents an exciting development. Feed-
ing trials were carried out with trout and kampachi,
allowing for an evaluation of diets with reduced
marine-derived ingredients but improved sustainability
criteria [27].
Further technical refinements have been made to the
transgenic approaches used to synthesised astaxanthin.
For example, an artificial glycine-rich polypetide linker
was used to fuse together bacterial CrtW and CrtZ
sequences, with the goal of increasing the flux of substrate
through to astaxanthin [28]. This approach was shown to
be successful in both prokaryotic and eukaryotic systems,
enhancing the accumulation of astaxanthin and decreas-
ing phoenicoxanthin and canthaxanthin [28], and may
represent a simple method by which to seed the assembly
of a metabolon.
Probably the best-known example of engineering the
accumulation of carotenoids in GM plants is Golden Rice,
which also represents one of the first (and still incomplete,
in terms of regulatory approval) examples of transgenic
nutritional enhancement [1]. A recent systematic re-
examination of the metabolic engineering of rice endo-
sperm for the accumulation of b-carotene confirmed the
importance of generating sufficient flux through the
methylerythritol 4-phosphate (MEP) pathway [29] and
also presented a new platform for the synthesis of
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Figure 2
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Schematic representation of the biosynthetic pathway for non-methylene-interrupted PUFAs in plants. The ubiquitous essential fatty acids linoleic
acid and a-linolenic acid can undergo either D5-desaturation to yield the C18 NMI-PUFAs pinolenic acid (PNA; n-6) or coniferonic acid (CON; n-3),
or undergo C2 D9-elongation to generate a methylene-interrupted intermediate eicosadienoic acid (EDA; n-6) or eicosatrienoic acid (ETA; n-3)
which then undergo D5-desaturation to yield the NMI-PUFAs sciadonic acid (SCA; n-6) or juniperonic acid (JPA; n-3). The same enzymes (D9-
elongase, D5-desaturase) recognise both omega-6 and omega-3 substrates.
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astaxanthin and other ketocarotenoids in a stable food
crop. Finally, in a very elegant and distinct approach,
transplastomic (as opposed to nuclear transformation) was
used to engineer tobacco plants with the capacity to
synthesise astaxanthin [30]. This took advantage of
the plastidial location of the MEP pathway which gen-
erates the isoprenoid precursors for carotenoid synthesis
and also the prokaryotic nature of this organelle which
makes it an obvious host for bacterial CrtW and CrtZ
genes. Stable transformation of the tobacco plastid
genome was successfully achieved, and high levels of
astaxanthin, but not other ketocarotenoids, was achieved
[30]. This plastidial trait was also transferable to related
Nicotiana species by grafting, since plastids are known to
migrate across grafts [30].
Anthocyanins
Anthocyanins comprise a large family of water-soluble
pigments, not only prized for their different hues and
colours, but also now recognised as being vital health-
protective components of the human diet [31]. They can
reduce the risk of CVD and related inflammatory-
response pathologies, as well as a number of cancers of
the digestive tract [32,33]. Although a wide range of
native organisms accumulate different anthocyanins,
many are not amenable or appropriate for cultivation
and/or harvest. Transgenic plants have been developed
as chassis for the synthesis of a designer palette of
anthocyanins with considerable success. Unlike the pre-
ceding examples of omega-3 fatty acids and ketocarote-
noids, accumulation of anthocyanins has been achieved
the overexpression of regulatory genes (i.e. transcription
factors), in addition to specific biosynthetic genes [34].
Such an approach has allowed for the high-level, tailored
synthesis of specific subclasses of anthocyanins, in both
transgenic plants [35] and cell suspension cultures [36].
Similar approaches of using transcription factors to upreg-
ulate whole classes of beneficial secondary metabolites
such as polyphenols have been used successfully [37], not
only providing a new sustainable production source but
also helping to elucidate the key enzymatic steps in the
biosynthesis of these compounds [37]. Certainly, the
contribution of transcription factors in the domestication
of a number of crops selected for their aroma and appear-
ance is now becoming apparent [38], helping to reveal-
ing a fascinating and complex pedigree and the blinded
contribution of man and environment [38,39]. Given
this greater understanding of the endogenous regulatory
factors which modulate the synthesis and accumulation of
health-beneficial phytochemicals and secondary metab-
olites, it should be possible to select plants via conven-
tional marker-assisted breeding techniques with superior
profiles for better human nutrition [2].
Conclusions
As described here, significant progress has been made in
the last few years to not only demonstrate the feasibility
of using transgenic plants as platforms to make a range of
health-beneficial compounds, but also to move further
down the translation pipeline ultimately towards regula-
tory approval, commercialisation and consumer uptake.
Part of this process involves the transition from a research
phase to a development mode [1], which not only takes
time and money but also an entirely different mindset
and approach. It is genuinely exciting that some of the
projects described above are already on that journey, and
it is to be hoped that soon there will be tangible products
from these efforts. But as recently noted [40] by Marc Van
Montagu, one of the ‘founding fathers’ of plant genetic
engineering, it will only be possible to capture the truly
big and disruptive innovations we require to meet the
challenges of the Sustainable Development Goals
(SDGs) if we work collaboratively with co-design
approaches and common goals endorsed by social license.
That, in turn, will likely needs a more thorough consid-
erations of consumer motivation [41] and the ethical
frameworks around the use of GM crops, as exemplified
in this thoughtful review [42].
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